Breast, gastric, lung, prostate, colorectal and other cancers Cancer, Breast cancer, Gastric cancer, Lung cancer, Prostate cancer, Colorectal cancer, Bladder cancer, Esophageal cancer, Pancreatic cancer, Ovarian cancer, Sarcoma, Brain tumor, Hepatocellular carcinoma, Biliary tract cancer, Cervical cancer, Endometrial cancer, Renal cell carcinoma, Head and neck cancer, microRNA, miRNA, early detection, blood test
Conditions
Interventions
None listed
Sponsors
Okada Yuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Stage 0 or Stage I/II patients and, as a comparison, Stage III/IV patients. 2) Patients who have not received medical therapy against cancer cells such as chemotherapy or radiation therapy. The following patients will also be included for preoperative and postoperative comparisons 3) Patients who have received surgical or medical treatment. In addition, patients who have not been diagnosed with cancer by a physician shall be included. Translated with DeepL.com (free version)
Exclusion criteria
Exclusion criteria: 1) Patients whose physician determines that there is a high probability of complications from bacterial infections. 2) Patients with an urgent and obvious life-threatening condition. 3) Other patients deemed inappropriate by the physician in charge of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composition and expression levels of circulating microRNAs (miRNAs) in patients diagnosed with cancer and in individuals without cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Types and composition of miRNAs detectable by cancer type Quantitative values of tumor markers Age and sex of research participants Medical history and treatment history Cancer stage (TNM classification or equivalent) | — |
Contacts
Public ContactYuki Okada
Setolabo Hygiene Laboratory
Outcome results
None listed